Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $70.38 USD
Change Today +0.27 / 0.39%
Volume 407.3K
CRL On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 8:04 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

charles river laboratories (CRL) Snapshot

Open
$70.02
Previous Close
$70.11
Day High
$70.50
Day Low
$68.86
52 Week High
03/20/15 - $84.69
52 Week Low
10/15/14 - $55.47
Market Cap
3.3B
Average Volume 10 Days
441.4K
EPS TTM
$3.06
Shares Outstanding
46.8M
EX-Date
--
P/E TM
23.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for CHARLES RIVER LABORATORIES (CRL)

charles river laboratories (CRL) Related Bloomberg News

View More Bloomberg News

charles river laboratories (CRL) Related Businessweek News

No Related Businessweek News Found

charles river laboratories (CRL) Details

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery and preclinical development services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also offers a range of services to assist its clients in supporting the use of research models in drug discovery and development comprising genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for identification of a druggable target within a cell through delivery of clinical drug candidates; and safety assessment services, which comprise bioanalysis, pharmacokinetics, drug metabolism, toxicology, and pathology services. The Manufacturing segment provides non-animal or in vitro methods for lot release testing of medical devices and injectable drugs for endotoxin contamination. This segment also offers specialized testing of biologics and devices that are outsourced by pharmaceutical and biotechnology companies; and specific pathogen free fertile chicken eggs and chickens for the manufacture of live viruses. The company serves pharmaceutical and biotechnology companies, contract research organizations, agricultural and chemical companies, life science and veterinary medicine companies, contract manufacturing organizations, medical device companies, diagnostic and other commercial entities, hospitals, academic institutions, and government agencies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

7,900 Employees
Last Reported Date: 02/17/15
Founded in 1947

charles river laboratories (CRL) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $1.1M
Corporate Executive Vice President and Presid...
Total Annual Compensation: $524.9K
Chief Scientific officer and Corporate Execut...
Total Annual Compensation: $518.1K
Chief Administrative Officer, General Counsel...
Total Annual Compensation: $587.5K
Compensation as of Fiscal Year 2014.

charles river laboratories (CRL) Key Developments

Charles River Laboratories International, Inc. Appoints David R. Smith as Corporate Executive Vice President and Chief Financial Officer

On August 12, 2015, Mr. David R. Smith was officially appointed as Charles River Laboratories International, Inc. Corporate Executive Vice President and Chief Financial Officer. Mr. Ackerman has assumed a new position with Charles River as Senior Financial Advisor. Mr. Smith joined Charles River through the acquisition of Argenta and BioFocus from Galapagos NV, where he was serving as Chief Executive Officer of its Galapagos Services division.

Charles River Laboratories International Renews Strategic Partnership Agreement with AstraZeneca

Charles River Laboratories International reported the extension of its strategic drug development partnership with AstraZeneca. Under the agreement, Charles River Laboratories International has extended its initial three-year partnership with AstraZeneca for an additional five-year period. With extension into 2020, Charles River retains its position as AstraZeneca's preferred strategic partner for outsourced regulated safety assessment and development DMPK (drug metabolism and pharmacokinetics).

Charles River Laboratories International, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 27, 2015; Increases Earnings Guidance for the Year 2015; Provides Earnings Guidance for the Third Quarter of 2015

Charles River Laboratories International, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 27, 2015. For the quarter, the company reported total revenue of $339,573,000 compared to $341,179,000 a year ago. Operating income was $55,735,000 compared to $51,025,000 a year ago. Income from continuing operations before income taxes was $60,328,000 compared to $50,541,000 a year ago. Net income attributable to common shareholders was $48,509,000 or $1.02 per diluted share compared to $35,264,000 or $0.74 per diluted share a year ago. The increase was primarily related to a $9.9 million, or $0.21 per diluted share, bargain purchase gain resulting from a small acquisition in the Avian Vaccine business during the second quarter of 2015. Operating income, excluding specified charges (non-GAAP) was $67,986,000 compared to $64,799,000 a year ago. Diluted earnings per share from continuing operations, excluding specified charges (non-GAAP) was $0.96 compared to $0.97 a year ago. Free cash flow improved significantly in the second quarter to $72.4 million compared to $47.7 million last year. The increase was primarily driven by 2 factors: a strong second quarter operating performance and the timing of cash inflows and outflows associated with certain tax items. CapEx increased to $13.9 million in the second quarter. For the six months period, the company reported total revenue of $659,987,000 compared to $640,547,000 a year ago. Operating income was $98,740,000 compared to $90,731,000 a year ago. Income from continuing operations before income taxes was $92,280,000 compared to $93,527,000 a year ago. Net income attributable to common shareholders was $80,050,000 or $1.68 per diluted share compared to $67,496,000 or $1.41 per diluted share a year ago. Operating income, excluding specified charges (non-GAAP) was $119,801,000 compared to $115,779,000 a year ago. Diluted earnings per share from continuing operations, excluding specified charges (non-GAAP) was $1.75 compared to $1.79 a year ago. Net cash provided by operating activities was $97,606,000 compared to $85,438,000 a year ago. Capital expenditures were $24,556,000 compared to $20,505,000 a year ago. The company provided earnings guidance for the year 2015. Primarily as a result of the acquisition of Celsis, which closed on July 24, the company is increasing constant-currency revenue guidance for 2015 to a range of 8.0% to 9.5%, and non-GAAP earnings per share guidance to a range of $3.60 to $3.70 compared to $3.55 to $3.65 as previously guided. Amortization of intangible assets expects to be $0.32 compared to $0.31 as previously guided. Operating losses expects to be $0.06 compared to $0.04 as previously guided. GAAP earnings per share expect to be $3.25 to $3.35 compared to $3.15 to $3.25 as previously guided. The company expects net interest expense to be at the high end of previous outlook of $12 million to $14 million in 2015, primarily reflecting the incremental interest expense from the Celsis acquisition and the capital lease. CapEx is estimate of up to $70 million for the year is unchanged. This amount will fund projects to expand capacity in the Safety Assessment business, including reopening Massachusetts facility in early 2016 and plans for other growth businesses. For the full year, the company expected the margin to be up 75 to 100 basis points where it was last year. Revenue is expected in the third quarter to be similar or slightly above the second quarter run rate. Non-GAAP EPS is expected to be in the low to mid-$0.90 range. And looking at the overall non-GAAP operating margin, because of some of the seasonality, the company expected that, that will be a little bit lower in the second half than it was in second quarter.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CRL:US $70.38 USD +0.27

CRL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bioanalytical Systems Inc $1.60 USD -0.04
Ergomed PLC 179.50 GBp 0.00
PAREXEL International Corp $67.49 USD -1.73
Quintiles Transnational Holdings Inc $75.24 USD +1.04
WuXi PharmaTech Cayman Inc $42.49 USD -0.20
View Industry Companies
 

Industry Analysis

CRL

Industry Average

Valuation CRL Industry Range
Price/Earnings 23.8x
Price/Sales 2.5x
Price/Book 4.7x
Price/Cash Flow 20.0x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHARLES RIVER LABORATORIES, please visit www.criver.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.